XLO - Xilio Therapeutics, Inc.
8.57
0.220 2.567%
Share volume: 40,392
Last Updated: 04-17-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.19%
PREVIOUS CLOSE
CHG
CHG%
$8.35
0.22
0.03%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-14-2024 | 08-08-2024 | 11-07-2024 | 03-11-2025 | 05-08-2025 | 11-13-2025 | 03-23-2026 | |
| Total revenue | 0.000 | 2.357 M | 2.263 M | 1.724 M | 2.930 M | 19.066 M | 13.686 M | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 2.357 M | 2.263 M | 1.724 M | 2.930 M | 19.066 M | 13.686 M | |
| inf% | -3.99% | -23.82% | 69.95% | 550.72% | -28.22% | |||
| Operating expenses | 16.539 M | 17.031 M | 17.066 M | 15.353 M | 16.781 M | 20.995 M | 25.522 M | |
| Selling general and admin | 6.139 M | 5.815 M | 6.307 M | 6.517 M | 8.515 M | 6.674 M | 7.400 M | |
| Research and development | 10.400 M | 11.216 M | 10.759 M | 8.836 M | 8.266 M | 14.321 M | 18.122 M | |
| Total expenses | 17.487 M | 17.061 M | 17.025 M | 15.353 M | 16.781 M | 20.995 M | 25.522 M | |
| -2.44% | -0.21% | -9.82% | 9.30% | 25.11% | 21.56% | |||
| Operating income | -17.487 M | -14.704 M | -14.762 M | -13.629 M | -13.851 M | -1.929 M | -11.836 M | |
| Ebit | -17.203 M | -13.925 M | -14.020 M | -13.629 M | -13.265 M | -907.000 K | -5.020 M | |
| Pretax income | -17.203 M | -13.925 M | -14.020 M | -15.434 M | -13.265 M | -907.000 K | -5.020 M | |
| -19.05% | 0.68% | 10.09% | -14.05% | -93.16% | 453.47% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -17.203 M | -13.925 M | -14.020 M | -13.093 M | -13.265 M | -907.000 K | -5.020 M | |
| 19.05% | -0.68% | 6.61% | -1.31% | 93.16% | -453.47% |